HC Wainwright Forecasts Higher Earnings for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – HC Wainwright upped their Q3 2025 earnings per share estimates for shares of Delcath Systems in a report released on Monday, October 20th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.02 for the quarter, up from their previous estimate of ($0.08). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.13 EPS, Q1 2026 earnings at $0.12 EPS, Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.19 EPS, FY2027 earnings at $1.45 EPS and FY2029 earnings at $2.52 EPS.

Several other analysts have also recently issued reports on the company. Craig Hallum reaffirmed a “buy” rating and set a $20.00 price objective on shares of Delcath Systems in a report on Tuesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Delcath Systems in a report on Wednesday, October 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 price target on shares of Delcath Systems in a research note on Tuesday. Finally, Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Delcath Systems Trading Down 9.0%

NASDAQ DCTH opened at $10.36 on Wednesday. The stock’s 50 day moving average is $11.03 and its 200 day moving average is $12.39. Delcath Systems has a 12 month low of $8.87 and a 12 month high of $18.23. The stock has a market cap of $362.39 million, a PE ratio of 207.20 and a beta of 0.84.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.05. The business had revenue of $24.16 million during the quarter, compared to the consensus estimate of $22.84 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently modified their holdings of DCTH. Capital Advisors Wealth Management LLC purchased a new position in Delcath Systems during the first quarter worth $891,000. Cannon Global Investment Management LLC acquired a new position in Delcath Systems in the 1st quarter valued at about $239,000. Principal Financial Group Inc. raised its stake in Delcath Systems by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company’s stock valued at $1,497,000 after purchasing an additional 2,437 shares during the last quarter. Palisades Investment Partners LLC lifted its holdings in Delcath Systems by 1.0% in the 1st quarter. Palisades Investment Partners LLC now owns 171,084 shares of the company’s stock valued at $2,178,000 after purchasing an additional 1,757 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft boosted its stake in shares of Delcath Systems by 46.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 24,903 shares of the company’s stock worth $317,000 after purchasing an additional 7,925 shares during the last quarter. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.